The 83rd Annual Scientific Meeting of the Japanese Circulation Society

Plenary session
How to perform the translational research in cardiomyopathy

ENGLISH

Chairperson: Masafumi Kitakaze
(Department of Clinical Medicine and Development National Cerebral and Cardiovascular Center)
Cardiomyopathy is one of the intractable diseases in Japan among various cardiovascular diseases and is very hard to be treated even in the present era. In Japan, cardiomyopathy is the most major cardiovascular disease for heart transplantation, suggesting that the medical or surgical treatment of cardiomyopathy has been vainly effective. We, cardiologists are urged to innovate the new and truly effective treatment strategy from not only medical but also social viewpoints. Indeed, Japanese Government has invested many grants for the investigation of the pathophysiology and novel treatment of cardiomyopathy for several decades, culminating in many important findings and novel suggestions to cure cardiomyopathy. In the basic research, the approach of molecular biology and pharmacology, and genome and genetic studies have revealed the abnormality of candidate genes and proteins for signal transduction, sarcomeres, receptors and channels in cardiomyocytes; in the clinical research, the clinical features have been revealed by cardiac echocardiogram, MRI and other novel biomarker studies and several candidates for the drugs of MYK-461/491 has been proposed. Nevertheless, the current treatment of cardiomyopathy is limited by the conventional treatment of heart failure such as beta-blockers and RAS/aldosterone blockers, and there is no drug specific to treat cardiomyopathy. The lack of the treatment of cardiomyopathy is a very unusual situation because there are many lines of evidence in the basic and clinical researches, hinting that the linkage between basic and clinical researches are not well organized because of immaturity of translational research of cardiomyopathy. We should share the method of the translational research such as establishment and application of disease-specific iPS cells, the novel models of cardiomyopathy using animals, tissues or cells, the unexpected experimental systems, development of new drugs, theoretical science targeting the treatment of cardiomyopathy. In the present plenary sessions, we should discuss how basic research can be translated in the clinical practice in the cardiomyopathy field (Translational Approach) and we also need to know what clinical practice expects in the basic research (Reverse Translational Approach). We should get into the core of cardiomyopathy with not merely walking around the core of cardiomyopathy. Let’s go for it to conquer cardiomyopahy and save the patients.

CLOSE

↑ pagetop

© 2018- The 83rd Annual Scientific Meeting of the Japanese Circulation Society. All Rights Reserved.